Emily Golden
University of Western Australia
14 Papers
20 Citations
Emily Golden is an academic researcher from University of Western Australia. The author has contributed to research in topics: Cholesterol oxidase & Protein structure. The author has an hindex of 9, co-authored 13 publications. Previous affiliations of Emily Golden include Harry Perkins Institute of Medical Research.
Chat about Author
Papers
Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer
Ciara Duffy,Anabel Sorolla,Anabel Sorolla,Edina Wang,Edina Wang,Emily Golden,Emily Golden,Eleanor A. Woodward,Eleanor A. Woodward,Kathleen Davern,Kathleen Davern,Diwei Ho,Elizabeth K. M. Johnstone,Elizabeth K. M. Johnstone,Elizabeth K. M. Johnstone,Kevin D. G. Pfleger,Andrew Redfern,K. Swaminathan Iyer,Boris Baer,Pilar Blancafort +19 more
- 01 Sep 2020
TL;DR: It is demonstrated that honeybee venom and its major component melittin potently induce cell death, particularly in the aggressive triple-negative and HER2-enriched breast cancer subtypes.
Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics
Anabel Sorolla,Edina Wang,Emily Golden,Ciara Duffy,Sónia Troeira Henriques,Andrew Redfern,Pilar Blancafort +6 more
TL;DR: Recent advances for the selective inhibition of major cancer oncoproteins via iPep approaches are outlined and the development of multimodal peptides to overcome limitations of the first generations of iPeps are discussed.
Rab GTPases: Emerging Oncogenes and Tumor Suppressive Regulators for the Editing of Survival Pathways in Cancer
Priya Darshini Gopal Krishnan,Priya Darshini Gopal Krishnan,Emily Golden,Eleanor A. Woodward,Nathan J. Pavlos,Pilar Blancafort,Pilar Blancafort +6 more
TL;DR: Deconstructing the signaling mechanisms modulated by Rab proteins during apoptosis could unveil underlying molecular mechanisms that may be exploited therapeutically to selectively target malignant cells.
77
Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides
Anabel Sorolla,Anabel Sorolla,Edina Wang,Tristan D. Clemons,Cameron W. Evans,Janice Hc Plani-Lam,Emily Golden,Ben Dessauvagie,Andrew Redfern,K. Swaminathan-Iyer,Pilar Blancafort,Pilar Blancafort +11 more
TL;DR: A targeted nanoformulation for docetaxel-PGMA-PAA-nanoparticles and interference peptides designed to specifically inhibit EN1 (EN1-iPeps) significantly reduced TNBC growth both in vitro and in vivo without showing toxicity.
46
The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer
Emily Golden,Emily Golden,Rabab Rashwan,Rabab Rashwan,Rabab Rashwan,Eleanor A. Woodward,Eleanor A. Woodward,Agustin Sgro,Agustin Sgro,Edina Wang,Edina Wang,Anabel Sorolla,Anabel Sorolla,Charlene Babra Waryah,Charlene Babra Waryah,Wan Jun Tie,Wan Jun Tie,Elisabet Cuyàs,Magdalena Ratajska,Magdalena Ratajska,Magdalena Ratajska,Iwona Kardaś,Piotr Kozlowski,Elizabeth K. M. Johnstone,Elizabeth K. M. Johnstone,Elizabeth K. M. Johnstone,Heng B. See,Heng B. See,Heng B. See,Ciara Duffy,Ciara Duffy,Jeremy Parry,Kim A. Lagerborg,Piotr Czapiewski,Javier A. Menendez,Adam Gorczyński,Bartosz Wasag,Kevin D. G. Pfleger,Christina Curtis,Bum-Kyu Lee,Jonghwan Kim,Joseph Cursons,Nathan J. Pavlos,Wojciech Biernat,Mohit Jain,Andrew J. Woo,Andrew J. Woo,Andrew Redfern,Pilar Blancafort +48 more
TL;DR: In this article, the AAMDC-overexpressing tumors may be sensitive to PI3K-AKT-mTORC1 blockers in combination with anti-estrogens.